The increasing interest in effective weight management has spurred considerable exploration into novel treatments. Lately , Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activator , has exhibited promising results in medical trials, indicating potential for considerab